Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) and Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Valuation & Earnings
This table compares Bright Minds Biosciences and Enlivex Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bright Minds Biosciences | N/A | N/A | -$5.47 million | ($0.50) | -77.78 |
| Enlivex Therapeutics | N/A | N/A | -$29.07 million | ($0.98) | -1.17 |
Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bright Minds Biosciences | 0 | 0 | 3 | 1 | 3.25 |
| Enlivex Therapeutics | 0 | 0 | 2 | 1 | 3.33 |
Bright Minds Biosciences presently has a consensus target price of $80.00, indicating a potential upside of 105.71%. Enlivex Therapeutics has a consensus target price of $9.50, indicating a potential upside of 729.69%. Given Enlivex Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Bright Minds Biosciences.
Profitability
This table compares Bright Minds Biosciences and Enlivex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bright Minds Biosciences | N/A | -58.55% | -53.79% |
| Enlivex Therapeutics | N/A | -67.57% | -58.45% |
Insider & Institutional Ownership
40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Bright Minds Biosciences has a beta of -6.52, suggesting that its share price is 752% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Summary
Bright Minds Biosciences beats Enlivex Therapeutics on 7 of the 11 factors compared between the two stocks.
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
